On June 12, 2020 AbbVie (NYSE:ABBV) reported that it has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited "mini-tender" offer, dated June 1, 2020, to purchase up to 1,500,000 shares of AbbVie common stock at $88.05 per share (Press release, AbbVie, JUN 12, 2020, View Source [SID1234561068]). The offer price is approximately 4.99 percent below the closing price of the AbbVie common stock on May 29, 2020 ($92.67), the last trading day before the date of the offer. AbbVie is not associated in any way with TRC Capital, its mini-tender offer, or the offer documentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AbbVie does not endorse TRC Capital’s offer. This mini-tender offer is at a price below the closing price for AbbVie’s shares (as of the day prior to the offer) and is subject to numerous conditions. AbbVie recommends that shareholders obtain current quotes for the shares, review terms and conditions, and consult with their broker.

AbbVie shareholders who have already tendered may withdraw their shares by providing the written notice described in the TRC Capital offering documents prior to the expiration of the offer, which is currently scheduled at 12:01 a.m. New York City time on June 30, 2020.

AbbVie encourages brokers, dealers, and other investors to review the SEC’s letter regarding broker-dealer mini-tender offer dissemination and disclosure, which can be found here: View Source

AbbVie requests that a copy of this news release be included with all distribution of materials related to TRC Capital’s offer for shares of AbbVie common stock.